The results showed that the expression of both PD-L1 and PD-1 was elevated in the tissues of patients with hypopharyngeal carcinoma, indicating that PD-L1 together with PD-1 may serve as potential biomarkers for treating hypopharyngeal carcinoma, and inhibition of PD-L1 may be a novel therapeutic approach to the management of hypopharyngeal carcinoma. The gene discussed is PDCD1; the disease is hypopharyngeal carcinoma.